2025
Positron Emission Tomography Radiotracers for Identification of Site of Recurrence in Prostate Cancer After Primary Treatment Failure
Bitar R, Zurita P, Martiniova L, Zurita A, Ravizzini G. Positron Emission Tomography Radiotracers for Identification of Site of Recurrence in Prostate Cancer After Primary Treatment Failure. Cancers 2025, 17: 1723. PMID: 40427220, PMCID: PMC12109795, DOI: 10.3390/cancers17101723.Peer-Reviewed Original ResearchProstate-specific membrane antigenProstate-specific antigenProstate cancerPositron emission tomographyPositron emission tomography radiotracersBiochemical recurrenceF-FDGUpregulation of amino acid transportersProstate-specific membrane antigen expressionBiochemical recurrence of prostate cancerInvestigate positron emission tomographySerum prostate-specific antigenRecurrence of prostate cancerPrimary treatment failurePSMA-targeted agentsSite of recurrencePrimary prostate cancerSalvage therapyF-fluciclovineLocalized diseaseTreatment failureDefinitive managementMembrane antigenInvestigational agentsRadionuclide therapy
2024
Long-Term Outcomes of Prostate-Specific Membrane Antigen–PET Imaging of Recurrent Prostate Cancer
Kunst N, Long J, Westvold S, Sprenkle P, Kim I, Saperstein L, Rabil M, Ghaffar U, Karnes R, Ma X, Gross C, Wang S, Leapman M. Long-Term Outcomes of Prostate-Specific Membrane Antigen–PET Imaging of Recurrent Prostate Cancer. JAMA Network Open 2024, 7: e2440591. PMID: 39441595, PMCID: PMC11581571, DOI: 10.1001/jamanetworkopen.2024.40591.Peer-Reviewed Original ResearchConceptsProstate-specific antigenProstate-specific antigen levelPSMA-PETRecurrent prostate cancerBiochemical recurrenceProstate cancerLong-term outcomesProstate-specific membrane antigen positron emission tomographyEvaluation of biochemical recurrenceDetection of biochemical recurrenceLife yearsConventional imagingDefinitive local therapyPSMA PET imagingProstate cancer deathDetection of metastasesRetrospective cohort studyBase case analysisIncremental life-yearsPositron emission tomographyDecision-analytic modelLocal therapyConventional imaging strategiesDelayed TreatmentDisease courseSociodemographic disparities in prostate cancer imaging
Sundaresan V, Lokeshwar S, Sutherland R, Sohoni N, Golos A, Ajjawi I, Leapman M. Sociodemographic disparities in prostate cancer imaging. Abdominal Radiology 2024, 1-9. PMID: 39325212, DOI: 10.1007/s00261-024-04603-2.Peer-Reviewed Original ResearchProstate cancer imagingProstate cancerProstate cancer diagnosisMonitoring of prostate cancerProstate multiparametric MRISociodemographic disparitiesProstate cancer treatmentEquitable cancer careBiochemical recurrenceFactors associated with disparitiesMultiparametric MRIActive surveillanceTreatment planningBlack patientsCancer outcomesTreatment workflowDiagnostic imagingCancer careDiagnosisRural settingsProstateImaging utilizationTreatmentPatientsCancer imagingAssociation Between the Decipher Genomic Classifier and Prostate Cancer Outcome in the Real-world Setting
Leapman M, Ho J, Liu Y, Filson C, Zhao X, Hakansson A, Proudfoot J, Davicioni E, Martin D, An Y, Seibert T, Lin D, Spratt D, Cooperberg M, Sprenkle P, Ross A. Association Between the Decipher Genomic Classifier and Prostate Cancer Outcome in the Real-world Setting. European Urology Oncology 2024 PMID: 39098389, DOI: 10.1016/j.euo.2024.07.010.Peer-Reviewed Original ResearchDecipher genomic classifierRisk of metastasisBiochemical recurrenceRadical prostatectomyGenomic classifierDecipher testProstate cancerProstate Risk Assessment Postsurgical ScoreRisk of biochemical recurrencePatient's prostate cancerRisk of cancer recurrencePathological risk factorsProstate cancer outcomesCox proportional hazards regressionRetrospective cohort studyElectronic health record dataReal-world settingsProportional hazards regressionHealth record dataReal-world practice settingsProstate biopsyRP specimensOncological outcomesPrognostic significanceMedian age
2023
Proteomic-based stratification of intermediate-risk prostate cancer patients
Zhong Q, Sun R, Aref A, Noor Z, Anees A, Zhu Y, Lucas N, Poulos R, Lyu M, Zhu T, Chen G, Wang Y, Ding X, Rutishauser D, Rupp N, Rueschoff J, Poyet C, Hermanns T, Fankhauser C, Martínez M, Shao W, Buljan M, Neumann J, Beyer A, Hains P, Reddel R, Robinson P, Aebersold R, Guo T, Wild P. Proteomic-based stratification of intermediate-risk prostate cancer patients. Life Science Alliance 2023, 7: e202302146. PMID: 38052461, PMCID: PMC10698198, DOI: 10.26508/lsa.202302146.Peer-Reviewed Original ResearchConceptsGleason grade groupBiochemical recurrenceRisk of biochemical recurrenceIntermediate-risk patientsNon-aggressive diseaseProstate cancer managementProstate cancer patientsMultivariate Cox regressionHigh-risk groupPatient treatment decisionsProstatic adenocarcinomaGleason gradePrognostic indicatorMatched tumorCancer managementCox regressionCancer patientsGrade groupTreatment decisionsPatientsSurvival analysisRisk scoreClinical applicationGleasonProstateFirst-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-resistant prostate cancer (mCRPC)
Autio K, Higano C, Nordquist L, Appleman L, Zhang T, Zhu X, Babiker H, Vogelzang N, Prasad S, Schweizer M, Madan R, Billotte S, Cavazos N, Bogg O, Li R, Chan K, Cho H, Kaneda M, Wang I, Zheng J, Tang S, Hollingsworth R, Kern K, Petrylak D. First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-resistant prostate cancer (mCRPC). Journal For ImmunoTherapy Of Cancer 2023, 11: e005702. PMID: 36948505, PMCID: PMC10040068, DOI: 10.1136/jitc-2022-005702.Peer-Reviewed Original ResearchConceptsMetastatic castration-resistant prostate cancerAndrogen deprivation therapyRadiographic progression-free survivalCastration-resistant prostate cancerPhase 1 studyBiochemical recurrenceProstate cancerImmunotherapy regimenMedian durationDose escalationMedian radiographic progression-free survivalAntigen-specific T cell responsesImmune-related adverse eventsRecommended phase 2 doseSpecific T cell responsesPhase 2 doseImmune checkpoint inhibitorsModest antitumor activityObjective response rateProgression-free survivalAntigen-specific immunityT cell responsesInfluenza-like illnessSignificant side effectsDeprivation therapySynthesizing and Applying Molecular Targeted Imaging Results in Patients With Prostate Cancer (RADAR VII)
Crawford E, Harris R, Slovin S, Concepcion R, Albala D, Gomella L, Orio P, Sellinger S, Petrylak D, Koo P. Synthesizing and Applying Molecular Targeted Imaging Results in Patients With Prostate Cancer (RADAR VII). JU Open Plus 2023, 1 DOI: 10.1097/ju9.00000000000000011.Peer-Reviewed Original ResearchProstate cancerNonmetastatic castrate-resistant prostate cancerClinical decisionCastrate-resistant prostate cancerConventional imagingLimited clinical dataTreatment of patientsFuture clinical trialsTreatment decision makingProstate cancer researchLimited available evidenceNuclear medicine specialistsLocalized diseaseMetastatic diseaseMedical oncologistsProspective studyBiochemical recurrenceClinical trialsRadiographic assessmentClinical dataMore robust recommendationsMedicine specialistsClinical experienceConsensus guidanceRadiation oncologists
2022
A phase I study of ADXS-504, a cancer type specific immunotherapy, for patients with biochemically recurrent prostate cancer.
Runcie K, Dallos M, Khan S, Gray J, Marco P, Ping L, LaTourette D, Anderson C, Spina C, Yu J, Deutsch I, Sheeri S, Gutierrez A, Stein M. A phase I study of ADXS-504, a cancer type specific immunotherapy, for patients with biochemically recurrent prostate cancer. Journal Of Clinical Oncology 2022, 40: tps5115-tps5115. DOI: 10.1200/jco.2022.40.16_suppl.tps5115.Peer-Reviewed Original ResearchAndrogen deprivation therapyProstate-specific antigenTumor-associated antigensBiochemical recurrenceProstate cancerRadiation therapyTumor microenvironmentRadical prostatectomyStudy treatmentPromote anti-tumor immune responsesAntigen-specific T cell responsesBiochemical recurrence of prostate cancerBiochemically recurrent prostate cancerCastration sensitive prostate cancerPSA responseTime to PSA progressionDose of study treatmentAnti-tumor immune responseStandard first-line treatmentEvidence of metastatic diseaseMyeloid-derived suppressor cellsImmunosuppressive regulatory T cellsPeptide antigensLive-attenuated Listeria monocytogenesRecurrent prostate cancer
2021
The Prognostic Association of Prostate MRI PI-RADS™ v2 Assessment Category and Risk of Biochemical Recurrence after Definitive Local Therapy for Prostate Cancer: A Systematic Review and Meta-Analysis
Rajwa P, Mori K, Huebner NA, Martin DT, Sprenkle PC, Weinreb JC, Ploussard G, Pradere B, Shariat SF, Leapman MS. The Prognostic Association of Prostate MRI PI-RADS™ v2 Assessment Category and Risk of Biochemical Recurrence after Definitive Local Therapy for Prostate Cancer: A Systematic Review and Meta-Analysis. Journal Of Urology 2021, 206: 507-516. PMID: 33904755, DOI: 10.1097/ju.0000000000001821.Peer-Reviewed Original ResearchConceptsRisk of BCRPI-RADS v2 scoreDefinitive local therapyBiochemical recurrencePrognostic significanceRadical prostatectomyProstate cancerV2 scoreLocal therapySystematic reviewMagnetic resonance imaging (MRI) classificationPrimary definitive treatmentIndependent prognostic significanceRisk of biasSignificant prostate cancerProstate Imaging ReportingPI-RADS v2Prostate cancer diagnosisWeb of ScienceReliable diagnostic toolOncologic outcomesDefinitive treatmentMRI findingsPI-RADSPrognostic association
2020
RNA-seq profile of African American men with a clinically localized prostate cancer
Nagaya N, Rosenfeld J, Lee G, Kim I. RNA-seq profile of African American men with a clinically localized prostate cancer. Prostate International 2020, 9: 125-131. PMID: 34692584, PMCID: PMC8498718, DOI: 10.1016/j.prnil.2020.11.002.Peer-Reviewed Original ResearchProstate cancer tissuesProstate cancerAfrican American menAA menCA menCancer tissuesPotential genetic risk factorSphingosine-1-phosphate signalingAmerican menExpression levelsGenetic risk factorsIngenuity Pathway AnalysisPathway analysisRNA sequencingPoor prognosisBiochemical recurrenceRadical prostatectomyRisk factorsLow expressionCancerMenCaucasiansSignificant differencesPatientsHigh rateAdvanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART II.
Lowrance W, Breau R, Chou R, Chapin B, Crispino T, Dreicer R, Jarrard D, Kibel A, Morgan T, Morgans A, Oh W, Resnick M, Zietman A, Cookson M. Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART II. Journal Of Urology 2020, 205: 22-29. PMID: 32960678, DOI: 10.1097/ju.0000000000001376.Peer-Reviewed Original ResearchMeSH KeywordsAblation TechniquesAndrogen AntagonistsAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantConsensusEvidence-Based MedicineHumansMaleMedical OncologyNeoplasm GradingNeoplasm StagingOsteoporosisOsteoporotic FracturesPrognosisProstatectomyProstatic Neoplasms, Castration-ResistantRadiotherapy, AdjuvantSocieties, MedicalTreatment OutcomeUnited StatesUrologyConceptsAdvanced prostate cancerProstate cancerManagement of patientsMetastatic hormone-sensitive prostate cancerHormone-sensitive prostate cancerCastration-resistant diseaseLocal treatment optionsCochrane Central Register of Controlled TrialsCentral Register of Controlled TrialsRegister of Controlled TrialsSystematic reviewCochrane Central RegisterCochrane Database of Systematic ReviewsDatabase of Systematic ReviewsAUA reviewBiochemical recurrenceMetastatic diseaseReviewed reference listsTreated patientsTreatment optionsCancer panelCochrane DatabaseTreatment recommendationsPatientsControlled TrialsAdvanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART I.
Lowrance W, Breau R, Chou R, Chapin B, Crispino T, Dreicer R, Jarrard D, Kibel A, Morgan T, Morgans A, Oh W, Resnick M, Zietman A, Cookson M. Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART I. Journal Of Urology 2020, 205: 14-21. PMID: 32960679, DOI: 10.1097/ju.0000000000001375.Peer-Reviewed Original ResearchMeSH KeywordsAblation TechniquesAndrogen AntagonistsAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantConsensusEvidence-Based MedicineHumansMaleMedical OncologyNeoplasm GradingNeoplasm StagingPrognosisProstatectomyProstatic NeoplasmsRadiotherapy, AdjuvantSocieties, MedicalTreatment OutcomeUnited StatesUrologyConceptsAdvanced prostate cancerProstate cancerMetastatic hormone-sensitive prostate cancerHormone-sensitive prostate cancerCastration-resistant diseaseLocal treatment optionsCochrane Central Register of Controlled TrialsCentral Register of Controlled TrialsManagement of patientsRegister of Controlled TrialsSystematic reviewCochrane Central RegisterCochrane Database of Systematic ReviewsDatabase of Systematic ReviewsAUA reviewBiochemical recurrenceMetastatic diseaseReviewed reference listsTreated patientsTreatment optionsCancer panelCochrane DatabaseTreatment recommendationsControlled TrialsPatientsRTOG 3506 (STEEL): A study of salvage radiotherapy with or without enzalutamide in recurrent prostate cancer following surgery.
Posadas E, Gay H, Pugh S, Morgan T, Yu J, Lechpammer S, Feng F. RTOG 3506 (STEEL): A study of salvage radiotherapy with or without enzalutamide in recurrent prostate cancer following surgery. Journal Of Clinical Oncology 2020, 38: tps5601-tps5601. DOI: 10.1200/jco.2020.38.15_suppl.tps5601.Peer-Reviewed Original ResearchAndrogen deprivation therapyProgression-free survivalHigh-risk featuresSalvage radiotherapyBiochemical recurrenceRadical prostatectomyProstate cancerSystemic therapyAndrogen receptorYears of androgen deprivation therapyOccurrence of biochemical failureStandard androgen deprivation therapyRandomized phase II studyIndividualization of radiotherapyNon-steroidal anti-androgenPersistently elevated PSADisease control rateRecurrent prostate cancerSeminal vesicle invasionPara-aortic nodesSuspicious lymph nodesPatient-reported toxicityRisk of progressionOne-sided alphaElevated PSAManagement of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019
Gillessen S, Attard G, Beer T, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow R, Chi K, Clarke N, Davis I, de Bono J, Drake C, Duran I, Eeles R, Efstathiou E, Evans C, Fanti S, Feng F, Fizazi K, Frydenberg M, Gleave M, Halabi S, Heidenreich A, Heinrich D, Higano C, Hofman M, Hussain M, James N, Kanesvaran R, Kantoff P, Khauli R, Leibowitz R, Logothetis C, Maluf F, Millman R, Morgans A, Morris M, Mottet N, Mrabti H, Murphy D, Murthy V, Oh W, Ost P, O'Sullivan J, Padhani A, Parker C, Poon D, Pritchard C, Reiter R, Roach M, Rubin M, Ryan C, Saad F, Sade J, Sartor O, Scher H, Shore N, Small E, Smith M, Soule H, Sternberg C, Steuber T, Suzuki H, Sweeney C, Sydes M, Taplin M, Tombal B, Türkeri L, van Oort I, Zapatero A, Omlin A. Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. European Urology 2020, 77: 508-547. PMID: 32001144, DOI: 10.1016/j.eururo.2020.01.012.Peer-Reviewed Original ResearchConceptsAdvanced Prostate Cancer Consensus ConferenceAdvanced prostate cancerProstate Cancer Consensus ConferenceCastration-resistant prostate cancerProstate cancer expertsProstate cancerConsensus questionsManagement of advanced prostate cancerMetastatic castration-resistant prostate cancerNonmetastatic castration-resistant prostate cancerInternational prostate cancer expertsAdvanced prostate cancer treatmentCancer expertsEffects of hormone therapyConsensus conferenceAdverse effects of hormone therapyLocally advanced diseaseProstate cancer managementLevel 1 evidenceProstate cancer treatmentManagement of patientsPatient-specific factorsClinical trial enrollmentMultidisciplinary decision makingBiochemical recurrence
2018
Comparison of a low-cost immunohistochemistry marker panel with a cell-cycle progression assay for the prediction of outcome after radical prostatectomy.
Leapman M, Nguyen H, Cowan J, Xue L, Stohr B, Simko J, Cooperberg M, Carroll P. Comparison of a low-cost immunohistochemistry marker panel with a cell-cycle progression assay for the prediction of outcome after radical prostatectomy. Journal Of Clinical Oncology 2018, 36: 118-118. DOI: 10.1200/jco.2018.36.6_suppl.118.Peer-Reviewed Original ResearchPCa-specific mortalityRadical prostatectomyBiochemical recurrenceCCP scoreIHC panelCell cycle progression scoreExpression statusERG expressionCox proportional hazards regressionRisk of BCRPositive ERG expressionProportional hazards regressionProstate cancer riskPrediction of outcomeHigh Ki67Median ageIndependent predictorsPathologic characteristicsHazards regressionPrognostic utilityIHC statusInstitutional databaseLocalized PCaC-indexImmunohistochemistry panelWrong to be Right
Kang JJ, Reiter RE, Kummer N, DeKernion J, Steinberg ML, King CR. Wrong to be Right. American Journal Of Clinical Oncology 2018, 41: 1-5. PMID: 26237192, PMCID: PMC6946377, DOI: 10.1097/coc.0000000000000216.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnalysis of VarianceCohort StudiesDatabases, FactualDisease-Free SurvivalFollow-Up StudiesHumansKaplan-Meier EstimateMaleMargins of ExcisionMiddle AgedMultivariate AnalysisNeoplasm GradingNeoplasm Recurrence, LocalProportional Hazards ModelsProstatectomyProstate-Specific AntigenProstatic NeoplasmsRetrospective StudiesRisk AssessmentSalvage TherapySurvival AnalysisTreatment OutcomeConceptsSalvage radiation therapyRadical prostatectomyT stageCox multivariate analysisIntrinsic risk factorsIatrogenic failuresPostoperative PSASRT PSASalvage radiationBiochemical progressionIndependent predictorsLocal recurrencePreoperative PSARelapse rateBiochemical relapseKaplan-MeierBiochemical recurrenceSurgical approachRP patientsRisk factorsSurgical techniqueGleason gradeRadiation therapySurgical pathologyConsecutive rises
2017
Risk stratification for disease progression in pT3 prostate cancer after robot-assisted radical prostatectomy
Hong J, Kwon Y, Kim I. Risk stratification for disease progression in pT3 prostate cancer after robot-assisted radical prostatectomy. Asian Journal Of Andrology 2017, 19: 700-706. PMID: 28230003, PMCID: PMC5676431, DOI: 10.4103/1008-682x.193569.Peer-Reviewed Original ResearchConceptsAdjuvant radiation therapyPT3 prostate cancerRobot-assisted radical prostatectomyPathologic Gleason scoreBiochemical recurrenceRadical prostatectomyClinical progressionProstate cancerLymphovascular invasionRisk stratificationRisk factorsDisease progressionMultivariate Cox proportional regression analysisCox proportional regression analysisAdverse pathologic featuresProportional regression analysisRisk stratification toolMore risk factorsStage pT3bFree survivalOncologic outcomesPathologic featuresStratification toolGleason scoreOptimal patient
2016
Constructing bayesian networks by integrating gene expression and copy number data identifies NLGN4Y as a novel regulator of prostate cancer progression
Gong Y, Wang L, Chippada-Venkata U, Dai X, Oh W, Zhu J. Constructing bayesian networks by integrating gene expression and copy number data identifies NLGN4Y as a novel regulator of prostate cancer progression. Oncotarget 2016, 7: 68688-68707. PMID: 27626693, PMCID: PMC5356583, DOI: 10.18632/oncotarget.11925.Peer-Reviewed Original ResearchConceptsProstate cancerProstate cancer progressionBiochemical recurrenceCopy number alteration dataGene expressionCopy number dataAssociated with high grade prostate cancerIncreased risk of BCRCancer progressionRisk of biochemical recurrenceRegulator of prostate cancer progressionHigh grade prostate cancerHeterogeneity of prostate cancerGrade prostate cancerSynaptic adhesionPC-3 cellsNegative regulatorNLGN4YDecreased cell proliferationInflammatory cytokine expressionGenesNeuronal cellsAlteration dataCytokine expressionPublished datasetsPathological and Biochemical Outcomes among African-American and Caucasian Men with Low Risk Prostate Cancer in the SEARCH Database: Implications for Active Surveillance Candidacy
Leapman MS, Freedland SJ, Aronson WJ, Kane CJ, Terris MK, Walker K, Amling CL, Carroll PR, Cooperberg MR. Pathological and Biochemical Outcomes among African-American and Caucasian Men with Low Risk Prostate Cancer in the SEARCH Database: Implications for Active Surveillance Candidacy. Journal Of Urology 2016, 196: 1408-1414. PMID: 27352635, PMCID: PMC5542578, DOI: 10.1016/j.juro.2016.06.086.Peer-Reviewed Original ResearchConceptsAfrican American raceLow-risk prostate cancerAfrican American menRisk prostate cancerCaucasian manProstate cancerPathological upgradingBiochemical recurrenceFive-year recurrence-free survival ratesClinical low‐risk prostate cancerClinical low-risk diseaseRecurrence-free survival ratesCox proportional hazards analysisBiochemical recurrence outcomesEqual-access health systemLow-risk diseaseCohort of patientsLow-risk tumorsPositive surgical marginsProportional hazards analysisSearch databasesSEARCH cohortRecurrence outcomesRisk diseaseRisk tumorsLong-Term Outcomes of Using Hyaluronic Acid-Carboxymethylcellulose Adhesion Barrier Film on the Neurovascular Bundle
Patel R, Modi P, Elsamra S, Kim I. Long-Term Outcomes of Using Hyaluronic Acid-Carboxymethylcellulose Adhesion Barrier Film on the Neurovascular Bundle. Journal Of Endourology 2016, 30: 709-713. PMID: 27072291, DOI: 10.1089/end.2016.0046.Peer-Reviewed Original ResearchMeSH KeywordsCarboxymethylcellulose SodiumErectile DysfunctionHumansHyaluronic AcidKaplan-Meier EstimateLaparoscopyMaleMiddle AgedNeoplasm Recurrence, LocalPenile ErectionPostoperative PeriodProspective StudiesProstatectomyProstate-Specific AntigenProstatic NeoplasmsRetrospective StudiesRobotic Surgical ProceduresTreatment OutcomeConceptsErectile functionNeurovascular bundleBiochemical recurrenceGood baseline erectile functionPreoperative prostate-specific antigenRobot-assisted laparoscopic prostatectomyBaseline erectile functionPreoperative SHIM scoreSexual Health InventoryAUA symptom scorePostoperative erectile functionKaplan-Meier analysisNerve-sparing prostatectomyProstate-specific antigenSignificant differencesMean SHIMSHIM scoreIndependent t-testMedian followOncologic outcomesConsecutive patientsOperative timeRetrospective reviewProstate sizeSymptom scores
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply